Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) saw unusually-strong trading volume on Wednesday . Approximately 14,900 shares changed hands during trading, a decline of 97% from the previous session’s volume of 536,942 shares.The stock last traded at $10.13 and had previously closed at $10.40.

A number of research analysts recently weighed in on ITCI shares. Royal Bank of Canada set a $26.00 target price on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $29.00 price target (up previously from $26.00) on shares of Intra-Cellular Therapies in a research note on Thursday, May 23rd. ValuEngine cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, JMP Securities lowered their price objective on Intra-Cellular Therapies from $24.00 to $21.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. Intra-Cellular Therapies presently has an average rating of “Buy” and an average price target of $23.88.

The firm’s fifty day moving average price is $8.88 and its 200 day moving average price is $11.78. The company has a quick ratio of 8.86, a current ratio of 8.86 and a debt-to-equity ratio of 0.08. The stock has a market cap of $564.67 million, a PE ratio of -3.56 and a beta of 1.19.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.83) by $0.15. As a group, analysts anticipate that Intra-Cellular Therapies Inc will post -3.39 earnings per share for the current fiscal year.

In other news, Director Christopher D. Alafi acquired 125,000 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was purchased at an average price of $8.52 per share, for a total transaction of $1,065,000.00. Following the completion of the transaction, the director now directly owns 341,223 shares in the company, valued at approximately $2,907,219.96. The acquisition was disclosed in a filing with the SEC, which is available through this link. 18.20% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of ITCI. Quantamental Technologies LLC purchased a new stake in shares of Intra-Cellular Therapies during the 2nd quarter valued at about $49,000. Bank of Montreal Can raised its position in Intra-Cellular Therapies by 114.4% during the second quarter. Bank of Montreal Can now owns 7,067 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 3,771 shares during the period. BNP Paribas Arbitrage SA raised its position in Intra-Cellular Therapies by 883.0% during the first quarter. BNP Paribas Arbitrage SA now owns 10,361 shares of the biopharmaceutical company’s stock valued at $126,000 after purchasing an additional 9,307 shares during the period. First Mercantile Trust Co. raised its position in Intra-Cellular Therapies by 12.3% during the first quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 1,265 shares during the period. Finally, Slow Capital Inc. bought a new stake in shares of Intra-Cellular Therapies in the 2nd quarter valued at approximately $195,000. 68.97% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Featured Article: How is inflation measured?

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.